Idorsia advances hypertension treatment with new data at 2024 American Heart Association (AHA) Scientific Sessions

Allschwil, Switzerland – 11 November 2024

Idorsia Ltd (ALTI: IDIA) today announced that new data on aprositentan, the first and only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, will be presented at the American Heart Association (AHA) annual Scientific Sessions 2024. It will take place in Chicago, Illinois, between November 16-18, 2024. AHA Scientific Sessions is the premier conference of its kind featuring leading global leaders in cardiovascular and brain health. On March 19, 2024, aprositentan was approved in the United States for the treatment of hypertension in combination with other antihypertensive medications to reduce blood pressure in adult patients who are inadequately controlled with other medications.

As the AHA celebrates its centennial, Idorsia’s Chief Scientific Officer, Martine Clozel, MD, was selected by a group of leaders in the field to participate in the training session “Maintaining Target Organ Health During Blood Pressure Control: Challenges and Triumphs.” presentation title “Targeting the endothelin system in hypertension”. The session will be held on November 17, 2024 in Room S103D (McCormick Place Convention Center) from 3:30 pm to 4:45 pm.

The following poster presentations will be moderated:

“Efficacy and safety of aprositentan in patients with resistant hypertension receiving at least 4 antihypertensive drugs, including beta (ss) blockers”, Weber M, et al. Region 1, Edited Digital Poster 1, 17 November 2024, 15:25 – 15:30.
“Lowering blood pressure in diabetic patients with resistant hypertension: results of the aprositentan PRECISION study”, Flack J, et al. Region 1, Edited Digital Poster 1, 17 November 2024, 15:35 – 15:40.

Additionally, the following two abstracts on aprositentan were among the best abstracts presented at the AHA’s Hypertension Scientific Sessions Specialty Conference in September 2024. To honor the highest-scoring abstracts, they were selected to be re-presented as poster presentations at the annual Scientific. Sessions, Science and Technology Hall, South Building, 3rd Floor, 17 November 2024, 15:15 – 16:15:

““A significant effect of aprositentan on albuminuria in patients with resistant hypertension”Weber M, et al.
“Efficacy and safety of aprositentan in patients with resistant hypertension and high NT-proBNP”, Weber M, et al.

You can find all summaries at. congress website.

Idorsia will also be present at AHA Scientific Sessions 2024 with its TRYVIO (aprocitentan) commercial and medical information booth. Visit the team at stand 1705.

a promotional product theater titled “New Era in Hypertension Treatment” It will be presented by Michael A. Weber, MD, Professor of Medicine, Department of Cardiovascular Medicine, State University of New York, on November 17, 2024, from 11:15 a.m. to 12:00 p.m.

Notes to the editor

About Aprocitentan
Aprositentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist that inhibits ET-1 binding to ET._A. and E.T._B. receptors. In May 2022, Idorsia announced positive results from the Phase 3 PRECISION study of aprositentan for the treatment of patients with resistant hypertension. Detailed results are published at: Lancet and was presented as a Recent Advances in Science presentation during the American Heart Association (AHA) Scientific Sessions in November 2022. You can find more details and comments in the special section. Press release and a investor webcast Prof., a researcher at PRECISION. Featuring Markus Schlaich. On March 19, 2024, aprositentan was approved in the United States as TRYVIO. On 27 June 2024, the European Commission granted a market authorization for JERAYGO (aprocitentan).

About Idorsia
Idorsia Ltd achieves more – We have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company with a strong scientific foundation.

Headquartered near Basel, Switzerland (a European biotechnology hub), Idorsia specializes in the discovery, development and commercialization of small molecules to transform the horizons of treatment options. Idorsia has a 25-year legacy of drug discovery, a broad portfolio of innovative drugs in pipeline, a team of experienced professionals spanning all disciplines from patient bedside to bedside, and commercial operations in Europe and North America; An ideal constellation to deliver innovative medicines to patients.

Idorsia was listed on the SIX Swiss Stock Exchange (ticker symbol: IDIA) in June 2017 and has more than 750 highly qualified experts dedicated to realizing our ambitious goals.

For more information please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected]
[email protected]
www.idorsia.com

The above information contains certain “forward-looking statements” that relate to the company’s business and can be identified by the use of forward-looking terminology such as “estimates,” “believes,” “expects,” “may,” “could.” by “expected”, “will”, “continue”, “should”, “will”, “seeking”, “pending” or “anticipates” or similar expressions or by discussion of strategies, plans or intentions. Such statements include descriptions of development programs and anticipated expenditures thereon, descriptions of new products the company is expected to introduce, and anticipated customer demand for such products and products across the company’s current portfolio. Such statements reflect the company’s current views regarding future events and certain Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. If materialized or underlying assumptions prove incorrect, actual results may differ materially from those described herein than those anticipated, believed, estimated or expected.

Related Posts